YOL150C Antibody

What is YOL150C and what specific epitopes does this antibody target?

YOL150C (UniProt No. Q08293) is a protein encoded by Saccharomyces cerevisiae (Baker's yeast). This polyclonal antibody is raised against recombinant YOL150C protein from S. cerevisiae strain ATCC 204508/S288c . The antibody recognizes multiple epitopes across the YOL150C protein structure, providing robust detection capabilities compared to monoclonal alternatives. Similar to other polyclonal antibodies used in yeast research, it offers higher avidity through multiple epitope binding, which is particularly advantageous when studying proteins with complex tertiary structures .

What validation methods confirm specificity of YOL150C Antibody?

The specificity of YOL150C Antibody should be validated through multiple complementary approaches:

• Western blot analysis showing a single band at the expected molecular weight

• Knockout/knockdown controls comparing wild-type with YOL150C-deficient yeast strains

• Peptide competition assays demonstrating signal reduction when pre-incubated with purified antigen

• Comparison with alternative YOL150C antibodies targeting different epitopes

These validation strategies mirror those used in therapeutic antibody development, where rigorous characterization of binding properties is essential . While manufacturer validation typically includes Western blot and ELISA , researchers should perform independent validation in their specific experimental systems.

What applications are supported by YOL150C Antibody?

YOL150C Antibody has been tested and validated for:

Similar to antibodies used in functional analysis of other yeast proteins, YOL150C Antibody can be optimized for additional applications beyond manufacturer testing by implementing appropriate buffer modifications and protocol adjustments .

How can cross-reactivity be assessed when using YOL150C Antibody in related yeast species?

Cross-reactivity assessment is essential when studying YOL150C homologs in non-S. cerevisiae species. Implement the following methodological approach:

• Perform sequence alignment analysis between YOL150C and potential homologs to identify conserved epitope regions

• Use competitive binding assays with recombinant proteins from multiple species

• Include parallel Western blots with lysates from multiple yeast species alongside S. cerevisiae

• Consider epitope mapping to identify the specific regions recognized by the antibody

This systematic approach resembles cross-reactivity assessment methods employed in therapeutic antibody development, where minimizing off-target binding is critical . Researchers can quantify cross-reactivity using BLI (biolayer interferometry) or SPR (surface plasmon resonance) to measure binding constants with homologous proteins .

What are the implications of YOL150C post-translational modifications for antibody detection?

Post-translational modifications (PTMs) can significantly impact epitope accessibility and antibody recognition. For YOL150C Antibody:

• Phosphorylation sites may alter antibody binding affinity or prevent recognition entirely

• Glycosylation patterns can mask epitopes in native conditions while being accessible in denatured states

• Ubiquitination may change protein migration patterns in SDS-PAGE

To address these challenges:

• Compare detection in native versus denatured conditions

• Use phosphatase or glycosidase treatments before immunoblotting to assess PTM influences

• Employ mass spectrometry to map PTMs and correlate with antibody binding efficiency

This approach parallels strategies used in therapeutic antibody development, where understanding PTM impact on epitope recognition is critical for efficacy .

How can YOL150C Antibody be integrated into quantitative proteomics workflows?

For quantitative analysis of YOL150C expression:

• Implement stable isotope labeling with amino acids in cell culture (SILAC) followed by immunoprecipitation with YOL150C Antibody

• Use fluorescence-based Western blot quantification with appropriate reference standards

• Develop a quantitative ELISA using purified YOL150C protein standards and the antibody as capture reagent

• Consider immunoprecipitation followed by mass spectrometry to quantify YOL150C and its interacting partners

These methodologies mirror advanced approaches in antibody-based proteomics, where combining antibody specificity with quantitative readouts provides deeper biological insights .

What controls are essential when using YOL150C Antibody in immunoblotting experiments?

Implement these critical controls to ensure reliable results:

This comprehensive control strategy ensures that signals observed are specific to YOL150C rather than technical artifacts, similar to the rigorous validation performed in therapeutic antibody development .

What are optimal sample preparation methods for detecting YOL150C in different subcellular fractions?

YOL150C detection across subcellular compartments requires tailored extraction methods:

• Total protein extraction: Mechanical disruption (glass beads) in the presence of protease inhibitors, followed by TCA precipitation or direct lysis in sample buffer

• Subcellular fractionation:

  • Mitochondrial fraction: Differential centrifugation followed by sucrose gradient purification

  • Nuclear fraction: Spheroplasting followed by gentle lysis and nuclear isolation

  • Membrane fraction: Detergent-based extraction with Triton X-100 or digitonin

• Native protein complexes: Mild non-ionic detergents (NP-40, 0.1-0.5%) with physiological buffer conditions

This methodological approach adapts techniques used in the characterization of cellular protein distribution patterns and is essential for accurate localization studies .

What strategies can resolve weak or absent signals when using YOL150C Antibody?

Implement a systematic troubleshooting approach to resolve detection issues:

• Protein expression verification:

  • Confirm YOL150C expression using RT-PCR or mass spectrometry

  • Verify sample integrity with alternative protein markers

• Antibody optimization:

  • Test increased antibody concentration (up to 1:100 dilution)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Evaluate alternative blocking agents (BSA vs. milk vs. commercial blockers)

• Signal enhancement:

  • Implement amplification systems (biotin-streptavidin, tyramide)

  • Use high-sensitivity ECL substrates

  • Consider membrane transfer optimization (PVDF vs. nitrocellulose, transfer conditions)

This optimization strategy parallels approaches used in detecting low-abundance proteins in clinical samples, where signal enhancement is critical .

How can batch-to-batch variability of YOL150C Antibody be addressed in longitudinal studies?

To minimize the impact of antibody lot variations:

• Purchase sufficient quantity of a single lot for complete study when possible

• Establish a validation protocol for each new lot:

  • Side-by-side comparison with previous lot using identical samples

  • Determination of optimal dilution for new lot

  • Calibration curves using recombinant standard

• Implement internal normalization standards:

  • Include reference samples across all experiments

  • Use ratio-based quantification relative to constant controls

This approach is similar to quality control strategies employed in clinical antibody testing, where reproducibility across reagent lots is essential for reliable longitudinal analysis .

How can YOL150C Antibody be used to study protein-protein interactions?

For comprehensive analysis of YOL150C protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use antibody-conjugated beads (direct approach)

  • Implement a two-step IP with protein A/G beads (indirect approach)

  • Compare stringent vs. mild washing conditions to distinguish strong and weak interactions

• Proximity-dependent labeling:

  • Combine YOL150C antibody with secondary antibodies conjugated to enzymes like BioID or APEX

  • Identify proximal proteins through biotinylation and streptavidin pulldown

• Crosslinking immunoprecipitation (CLIP):

  • Use formaldehyde or specific crosslinkers to capture transient interactions

  • Combine with mass spectrometry for unbiased interactome analysis

These approaches adapt methods used in studying complex formation with therapeutic monoclonal antibodies, where understanding protein-protein interactions is essential for mechanism elucidation .

What considerations are important when using YOL150C Antibody for chromatin immunoprecipitation (ChIP) studies?

For successful ChIP implementation with YOL150C Antibody:

• Crosslinking optimization:

  • Test multiple formaldehyde concentrations (0.5-3%)

  • Evaluate dual crosslinkers (formaldehyde + DSG) for enhanced complex stabilization

• Chromatin fragmentation:

  • Optimize sonication parameters for 200-500bp fragments

  • Consider enzymatic digestion alternatives like MNase

• IP conditions:

  • Implement low-detergent buffers to preserve protein-DNA interactions

  • Increase antibody:chromatin ratio compared to standard IP protocols

  • Include competing agents (tRNA, salmon sperm DNA) to reduce non-specific binding

• Controls:

  • IgG control from same species as YOL150C Antibody

  • Input DNA normalization

  • Positive control targeting known DNA-binding protein

This methodology adapts ChIP approaches used for transcription factor studies to the analysis of YOL150C DNA interactions, if applicable to your research model .

How can flow cytometry be optimized for intracellular YOL150C detection using this antibody?

While not explicitly validated for flow cytometry, YOL150C Antibody may be adapted for flow cytometric analysis with these methodological considerations:

• Cell preparation:

  • Optimize fixation (2-4% paraformaldehyde, 10-20 minutes)

  • Test multiple permeabilization reagents (methanol, saponin, Triton X-100)

  • Include RNase treatment to reduce background

• Antibody optimization:

  • Test concentration range (1:50-1:500)

  • Extend incubation times (1-4 hours or overnight)

  • Compare different fluorophore-conjugated secondary antibodies

• Controls:

  • YOL150C knockout strain

  • Isotype-matched control antibody

  • Secondary antibody alone

  • Blocking peptide competition

This approach adapts methods used for detecting intracellular antigens in mammalian cells to yeast applications .

What are the considerations for multiplexed imaging using YOL150C Antibody?

For successful multi-protein detection alongside YOL150C:

• Primary antibody compatibility:

  • Select additional antibodies from different host species

  • When using multiple rabbit antibodies, implement sequential immunostaining with complete stripping between rounds

• Signal separation strategies:

  • Use spectrally distinct fluorophores with minimal overlap

  • Implement linear unmixing algorithms for closely related emission spectra

  • Consider signal amplification for low-abundance targets only

• Validation approaches:

  • Single-stain controls for each antibody

  • Fluorescence minus one (FMO) controls

  • Cross-reactivity assessment between secondary antibodies

This multiplexing strategy adapts approaches from clinical tissue analysis to yeast cellular imaging, maximizing information yield while maintaining signal specificity .